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Kidneys are enlarged by aberrant proliferation of tubule epithelial cells leading to the formation of numerous cysts, nephron loss,
and interstitial ﬁbrosis in polycystic kidney disease (PKD). Pioglitazone (PIO), a PPAR-γ agonist, decreased cell proliferation,
interstitial ﬁbrosis, and inﬂammation, and ameliorated PKD progression in PCK rats (Am. J. Physiol.-Renal, 2011). To explore
genetic mechanisms involved, changes in global gene expression were analyzed. By Gene Set Enrichment Analysis of 30655 genes,
13 of the top 20 downregulated gene ontology biological process gene sets and six of the top 20 curated gene set canonical
pathways identiﬁed to be downregulated by PIOtreatment were related to cell cycle and proliferation, including EGF, PDGF and
JNK pathways. Their relevant pathways were identiﬁed using the Kyoto Encyclopedia of Gene and Genomes database. Stearoyl-
coenzyme A desaturase 1 is a key enzyme in fatty acid metabolism found in the top 5 genes downregulated by PIO treatment.
Immunohistochemical analysis revealed that the gene product of this enzyme was highly expressed in PCK kidneys and decreased
by PIO. These data show that PIO alters the expression of genes involved in cell cycle progression, cell proliferation, and fatty acid
metabolism.
1.Introduction
Polycystic kidney diseases (PKD) are characterized by pro-
gressive enlargement of numerous ﬂuid-ﬁlled cysts in both
kidneys, often leading to chronic kidney disease (CKD).
Autosomal dominant PKD (ADPKD) is one of the most
common hereditary disorders in humans with an inci-
dence of 1:500–1,000, caused by mutations in the PKD1
or PKD2 gene. Progressive kidney enlargement is due to
aberrant proliferation of the cystic epithelia, together with
an accumulation of ﬂuid into the cyst cavities due to
transepithelial chloride (Cl−) and ﬂuid secretion [1–3].
Autosomal recessive PKD (ARPKD) is known as a juvenile-
type cystic disease with an incidence of 1:20,000 [3].
Kidneys in ARPKD patients are characterized by cystic
fusiform dilations of the collecting ducts accompanied by
increased cell proliferation and ﬂuid secretion, leading to
massive kidney enlargement and renal failure occurring in
the ﬁrst few years after birth [4]. Increased cell prolifera-
tion, stimulated ﬂuid secretion, and interstitial ﬁbrosis are
often observed in cystic liver disease in ARPKD as well
[5].2 PPAR Research
Peroxisome proliferator-activated receptors (PPARs)
belong to a nuclear receptor superfamily of ligand-activated
transcription factors with subtypes α, β/δ,a n dγ.P P A R - γ
is widely expressed in several organs including kidneys and
known to be activated by fatty acids [6, 7]. Antidiabetic
agents, pioglitazone (PIO), troglitazone, ciglitazone, and
rosiglitazone, are used to control blood sugar levels in
patients with diabetes mellitus. These PPAR-γ agonists also
have important roles in regulation of cell cycle, inhibition
of ﬁbrosis, inﬁltration and metastasis of cancer cells, and
modulation of inﬂammatory cytokines.
Treatment with PIO improved survival and ameliorated
cardiac defects and the degree of renal cystogenesis in
embryosofPkd1−/− miceinapreviousstudy[8].Inaddition,
long-term treatment of this agonist improved endothelial
function by increasing production of nitric oxide in adult
heterozygous Pkd1+/− mice [8]. Another PPAR-γ agonist,
rosiglitazone attenuated PKD progression and prolonged
survival of Han: SPRD Cy rats [9]. In our recent study,
daily treatment of PIO ameliorated polycystic kidney dis-
ease through inhibiting Raf/MEK/ERK and AKT/mTOR/S6
signaling cascades in the PCK rat, an orthologous model of
human ARPKD [10]. These ﬁndings suggest that PPAR-γ
agonists may have therapeutic value in ARPKD via altering
several cellular signaling pathways. In the current study,
we applied global gene expression proﬁling to explore
novel cellular signaling pathways potentially related to the
ameliorating eﬀects of PIO in PCK rat kidneys.
2. Methods
2.1. PCK Rat and Study Design. PCK rats were originally
derived from a strain of Sprague-Dawley rats in Japan
and descendants of this colony have been maintained at
the Education and Research Center of Animal Models for
Human Diseases, Fujita Health University. PCK rats and
normal Sprague Dawley rats (+/+; Charles River Japan
Inc., Kanagawa, Japan) were allowed free access to water
and food throughout the study. Female PCK and +/+ rats,
aged 4–20 weeks (n = 10 per gender) were randomly
assigned to one of two groups: treatment with 10mg/kg PIO
(Takeda Pharmaceutical Company Limited, Osaka, Japan)
or vehicle control (0.5% DMSO) by gavage every day as
previously reported [10]. The protocol for the ethics and use
of these animals was approved by the Animal Care and Use
Committee at Fujita Health University.
At 20 weeks of age, rats were anesthetized with sodium
pentobarbital (Schering-Plough Corp., Kenilworth, NJ), and
thekidneyswereremovedrapidly,causinglethalexsanguina-
tion. Half of the left kidney was frozen in liquid nitrogen for
RNA extraction. Half of the right kidney was immersed in
4% paraformaldehyde, embedded in paraﬃn, and sectioned
for immunohistochemistry.
2.2. RNA Extraction. RNA was extracted from kidneys of
rats with or without PIO treatment using a monophasic
solution of phenol/guanidine isothiocyanate and TRIzol
reagent (Invitrogen Co., Carlsbad, CA, USA) in accordance
with their manual, and the samples were incubated with
RNase-free DNase I (Ambion, TX, USA). The quality and
concentration of each sample was conﬁrmed by spectropho-
tometry (NanoDrop ND-1000; Asahi glass Co. Ltd., Tokyo,
Japan).TotalRNAobtainedfromthreefemaleswaspooledin
each PIO-treated or control vehicle-treated (CONT) group
in accordance with our previous report [11].
2.3. Microarrays. DNA microarray experiments were per-
formed essentially as described previously [11]. Brieﬂy,
500ng aliquots of total RNA obtained from kidneys of
ﬁve rats were labeled using a Quick Amp Labeling Kit,
one-color (Agilent Technologies, Inc., Santa Clara, CA,
USA), according to the manufacturer’s instructions. The
pooled renal RNA of PIO- or vehicle-treated PCK rats were
labeled with the Cy3-ﬂuorescence dye. After determination
of labeling eﬃciency, 1.65μg aliquots of Cy3-labeled RNA
were hybridized using the Gene Expression hybridization
kit (Agilent Technologies) onto Rat Oligo Microarrays
(Agilent Technologies, product no. G4130A) according to
the manufacturer’s hybridization protocol. The microarray
slideswereexaminedwithanAgilentmicroarrayscannerand
software. Data analysis was performed with Agilent Feature
Extraction software (version A.7.1.1).
Data from microarray experiments of PIO- or vehicle-
treated rats were analyzed independently. Primary microar-
ray data are available from the Gene Expression Omnibus
(GEO) (accession number GSE00000). Evaluation of signal
intensity was divided into three classes, {0}:n o n d e t e c t e d ,
{1}: weakly detected, and {2}:s t r o n g l yd e t e c t e dt r a n -
scription product. Gene ontology analysis of biological
process (C5BP) and curated gene sets of canonical pathways
(C2CP) were analyzed by importing the data into Gene
Set Enrichment Analysis (GSEA version 2, the Broad Insti-
tute/Massachusetts Institute of technology, USA) [12].
Using the GeneSpring software, the changed probes were
listed as “Log2 ratio was over 1 (over 2-fold) or less than −1
(less than 1/2-fold) between PIO group and CONT group”
and “the signal evaluation was {2} (strongly detected) in
both groups”. In the changed genes, Kyoto Encyclopedia of
Gene and Genomes (KEGG) analysis was used [13].
2.4. Real-Time Reverse Transcriptase Polymerase Chain Reac-
tion (RT-PCR). cDNA was produced from total RNA
by reverse transcriptase using random hexamer primers
(SuperScript II First Strand Synthesis System; Invitrogen
Co., Carlsbad, CA, USA). To compare gene expression
patterns of PCK kidneys with PIO or vehicle treatment,
we selected a key enzyme in fatty acid metabolism,
stearoyl-coenzyme A desaturase 1 (Scd1), and uncou-
pling protein 1 (Ucp1). Gene expression was detected
by real-time RT-PCR (ABI 7300 real-time PCR system;
Applied Biosystems, Foster City, CA, USA) using the Taq-
Man reagent-based chemistry protocol. Glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) as a housekeeping gene
was used for data normalization. The probes of Scd1, UCP-1,
and GAPDH were CCCACATGCTCCAAGAGATCTCCAG,
CTCTTCAGGGAGAGAAACGCCTGCC, and AACCCAT-
CACCATCTTCCAGGAGCG, respectively (TaqMan GenePPAR Research 3
Table 1: (a) Top 20 downregulated gene ontology biological process gene sets in PIO-treated compared with vehicle-treated kidneys. The
name of biological process is listed in order of nominal P value. (b) Upregulated gene ontology biological process gene sets in PIO-treated
compared with vehicle-treated kidneys. The name of biological process is listed in order of nominal P value.
(a)
Name of biological process gene sets Number of genes in the gene set Nominal P value
Defense response 98 0.000
Regulation of cell proliferation 136 0.000
Cell cycle phase 53 0.000
Positive regulation of cell proliferation 64 0.000
Cell cycle process 61 0.000
Positive regulation of cellular process 258 0.000
Cellular morphogenesis during diﬀerentiation 22 0.001
Positive regulation of developmental process 91 0.001
Immune system process 128 0.001
Cellular defense response 19 0.003
Neuron diﬀerentiation 35 0.004
Negative regulation of cell proliferation 73 0.004
Neurite development 27 0.005
G Protein signaling coupled to ip3 second messenger phospholipase C activating 22 0.005
Inﬂammatory response 56 0.005
Regulation of response to stimulus 15 0.006
Neuron development 30 0.007
Mp h a s e 27 0.007
Interphase 29 0.008
Axonogenesis 21 0.009
(b)
Name of biological process gene sets Number of genes in the gene set Nominal P value
Nitrogen compound catabolic process 17 0.000
Amine catabolic process 15 0.000
Amino acid metabolic process 46 0.000
Amino acid and derivative metabolic process 58 0.000
Organic acid metabolic process 106 0.000
Carboxylic acid metabolic process 104 0.022
Expression Assays; Applied Biosystems). Relative quantiﬁca-
tion of gene expression was compared to one in SD control
vehicle-treated (CONT) kidneys (set to 1.0).
2.5. Immunohistochemistry. Kidney sections were ﬁxed,
embedded, and sectioned for immunoreaction as described
previously [10, 11]. Sections were incubated with Scd1
antibody (1:250 ab19862 Abcam, Cambridge, UK) in PBS
containing 1% BSA plus 0.05% NaN3 overnight at 4◦C. To
test for a speciﬁc Scd1 immunoreaction in the kidney, mouse
IgG2b, κisotypecontrolantibody(1:200400323BioLegend,
San Diego, CA), was used. Sections were incubated with
secondary antibody Histoﬁne MAX-PO (MULTI: for anti-
mouse/rabbit IgG, IgA, and IgM) obtained from Nichirei
Biosciences (Tokyo, Japan). Immune reaction products
were developed using 3,3 -diaminobenzidine (ENVISION
kit HRP Dako Cytomation K3466, Dako Japan Inc., Tokyo,
Japan).
2.6. Statistical Analysis. Results are expressed as the arith-
metic mean ± standard error. Statistical comparisons
between groups were performed by Student’s t-test and two-
way analysis of variance, and diﬀerences were considered to
be signiﬁcant at P<0.05.
3. Results
3.1. Identiﬁcation of Diﬀerentially Expressed Genes by Expres-
sion Proﬁling. Previous report indicates that PPAR-γ agonis-
tic action decreases expression of endothelin receptor type
A (EDNRA) [14], suggesting that EDNRA is one of the
down-stream target gene of PPAR-γ agonists. In our current
study, expression of Ednra was also downregulated in PIO-
treated kidneys (Log2 ratio = −1.30). EDNRA expression
is increased in human ADPKD, and overexpression of
Ednra causes cyst formation in transgenic mouse kidneys
[15]. Because not only EDNRA but also various genes4 PPAR Research
Table 2: (a) Downregulated gene ontology biological process gene sets from genes with greater than 1.25-fold changes in PIO-treated
compared with vehicle-treated kidneys. The name of biological process is listed in order of nominal P value. (b) Common genes found in
cell cycle orcell proliferation gene setsdownregulated by PIOtreatment.:listedgene inthegene set, —:non-listedgene in thegene set.(c)
Upregulated gene ontology biological process gene sets with greater than 1.25-fold changes in PIO-treatmed compared with vehicle-treated
kidneys.
(a)
Name of biological process gene sets Number of genes in the gene set Nominal P value
Carbohydrate METABOLIC PROCESS 16 0.019
Cell proliferation GO 0008283 70 0.024
Organelle organization and biogenesis 34 0.025
Cell cycle GO 0007049 44 0.027
Negative regulation of cell proliferation 28 0.032
Cell cycle process 31 0.037
(b)
Gene symbol Description
Name of biological process gene sets
Cell cycle GO 0007049
Negative
regulation of
cell proliferation
Cell cycle process
Cell
proliferation
GO 0008283
Brca2 Breast cancer 2  
Cdkn2b
Cyclin-dependent
kinase inhibitor 2B
(p15, inhibits CDK4)
 
Chek1 CHK1 checkpoint
homolog   —
BUB1B
Cell cycle checkpoint
protein kinase Bub1
Fragment
 — 
PLK1 Pololike kinase 1  — 
Cdkn1c Cyclin-dependent
kinase inhibitor 1C   —
Cul5 Cullin 5  
Tgfb2 Transforming growth
factor, beta 2  — 
Bcat1 Branched chain
aminotransferase 1  — 
PTPRC
Protein tyrosine
phosphatase, receptor
type, C
 — 
POLA1 Polymerase (DNA
directed), alpha 1  — 
(c)
Name of biological process gene sets Number of genes in the gene set Nominal P value
Neurological System Process 40 0.032
may be inﬂuenced by PPAR-γ agonistic actions, it became
intriguing to determine the expression of other potential
gene targets of PIO in PCK rat kidneys. 30,655 of 43,379
probes yielded detectable signals in both PIO- and vehicle-
treated kidneys of PCK rats. The 11,809 genes represented
by these 30,655 probes were analyzed by GSEA. In gene
ontology analysis of biological process (C5BP) gene sets, 334
were formed from these 11,809 genes. 293 of those 334 gene
sets were downregulated in PIO-treated kidneys compared
with vehicle-treated kidneys, of which 77 were signiﬁcantly
diﬀerent (P<0.05, Table 1(a)). In the top 20 downregulated
C5BP gene sets with the greatest signiﬁcant diﬀerences, 13
were related to cell proliferation, cell cycle, morphogenesis,
diﬀerentiation, and development, and 4 gene sets were
related to cellular defense and inﬂammation. On the other
hand,41ofthe334genesetswereupregulatedinPIO-treatedPPAR Research 5
kidneys compared with vehicle-treated kidneys, of which 6
weresigniﬁcantlydiﬀerent(P<0.05,Table 1(b)).Thesegene
sets were related to catabolic and metabolic processes.
To examine the gene sets with the greatest changes,
only 2,611 genes, which changed more than 1.25-fold in
PIO-treated kidneys compared to vehicle-treated kidneys,
were analyzed. 141 gene sets were formed from these 2,611
genes. 112 of those 141 gene sets were downregulated in
PIO-treated kidneys compared with vehicle-treated kidneys
of PCK rats. Of these, 6 gene sets were signiﬁcantly diﬀerent
(P<0.05, Table 2(a)). 4 of these 6 gene sets are related
to cell cycle and cell proliferation (Table 2(a)). Common
genes in these gene sets include G1/S or G2/M checkpoint
related genes, breast cancer 2 (Brca2), cyclin-dependent
kinase inhibitor 2B (Cdkn2b), CHK1 checkpoint homolog
(Chek1), cell cycle checkpoint protein kinase Bub1 fragment
(BUB1B), pololike kinase 1 (PLK1), and cyclin-dependent
kinase inhibitor 1C (Cdkn1c)( Table 2(b)). Of the remaining
29 of the 141 gene sets that were upregulated in PIO-treated
kidneys compared with vehicle-treated kidneys, only one,
related to neurological system processes, was signiﬁcantly
elevated (P<0.05) (Table 2(c)).
In curated gene sets of canonical pathways (C2CP), 257
were formed from the 11,809 genes detected. 201 of these
257 gene sets were downregulated in PIO-treated kidneys
compared with vehicle-treated kidneys, of which 33 were
signiﬁcantly lower (P<0.05). From the 20 downregulated
C2CP gene sets with the highest signiﬁcant diﬀerences
(lowest P values), 6 gene sets were related to cell cycle
and cell proliferation including c-Jun N-terminal kinase
(JNK) ,e p i d e r m a lg r o w t hf a c t o r( EGF), and platelet-derived
growth factor (PDGF) pathways, and 3 gene sets were related
to inﬂammatory signals including interleukin-1 receptor
(IL1R) and interleukin-6 (IL6)p a t h w a y s( Table 3(a)). One
gene set, extracellular matrix (ECM) receptor interaction,
also was in the top 20 downregulated in C2CP. On the other
hand, 56 of 257 gene sets were upregulated in PIO-treated
kidneys compared with vehicle-treated kidneys, of which 5
gene sets were signiﬁcantly higher (P<0.05, Table 3(b)).
3 of these 5 gene sets are related to glutamate, alanine, and
aspartate metabolism.
GSEA is a computational method that determines
whether an a priori deﬁned set of genes shows statistically
signiﬁcant and concordant diﬀerences between two biolog-
ical states and can detect important biological processes
or canonical pathways by using the list rank information
without using a threshold [12]. Among the 43,379 probes
spottedonthemicroarrayslide,189probesweresigniﬁcantly
changed. From these 189 probes, 31 genes were identiﬁed
by KEGG analysis. 23 of those 31 genes were downregu-
lated in PIO-treated compared with vehicle-treated kidneys
(Table 4(a)). Two key enzymes in fatty acid metabolism,
stearoyl-coenzyme A desaturase 1 (Scd1) and uncoupling
protein 1 (Ucp1), which are involved in PPAR signaling
were in the top 15 genes downregulated by PIO treatment.
On the other hand, 8 of the 31 genes were upregulated in
PIO-treated kidneys compared with vehicle-treated kidneys
(Table 4(b)).
Table 3: (a) Top 20 downregulated curated gene sets of canonical
pathways in PIO-treated compared with vehicle-treated kidneys.
The name of biological process is listed in order of nominal P
value. (b) Upregulated curated gene sets of canonical pathways in
PIO-treated compared with vehicle-treated kidneys. The name of
biological process is listed in order of nominal P value.
(a)
Name of biological process gene sets
Number of
genes in
the gene
set
Nominal
P value
HSA04640 hematopoietic cell lineage 32 0.000
HSA04610 complement and coagulation
cascades 37 0.000
HSA04510 focal adhesion 110 0.001
Breast cancer estrogen signaling 60 0.001
HSA04060 cytokine cytokine receptor
interaction 99 0.002
HSA04912 GNRH Signaling Pathway 64 0.002
HSA04110 cell cycle 44 0.003
HSA01430 cell communication 39 0.004
IL1R pathway 15 0.007
Eicosanoid synthesis 15 0.009
HSA04512 ECM receptor interaction 41 0.009
Cell cycle KEGG 34 0.012
ST JNK MAPK pathway 17 0.017
EGF pathway 23 0.023
PDGF pathway 23 0.028
FCER1 pathway 26 0.029
GSK3 pathway 18 0.029
Prostaglandin and leukotriene
metabolism 19 0.032
IL6 pathway 17 0.032
HSA02010 ABC transporters general 21 0.033
(b)
Name of biological process gene sets
Number of
genes in
the gene
set
Nominal
P value
HSA00190 oxidative phosphorylation 37 0.000
Glutamate metabolism 15 0.000
HSA00252 alanine and aspartate
metabolism 17 0.010
HSA00710 carbon ﬁxation 15 0.019
HSA00251 glutamate metabolism 17 0.019
3.2. Cellular Expression and Distribution of Scd1 in Rodent
Polycystic Kidneys. For Scd1 and Ucp1,i no r d e rt oc o n ﬁ r m
the mRNA expression by DNA microarray screening above,
real-time RT-PCR analysis was performed. The mRNA level
of Scd1 in the kidney was increased in PCK rats compared6 PPAR Research
Table 4: (a) Downregulated genes in PIO-treated compared with vehicle-treated (CONT) kidneys of PCK rats. The name of gene symbol
was listed in order of PIO/CONT Log2 ratio. (b) Upregulated genes in PIO-treated compared with vehicle-treated (CONT) kidneys of PCK
rats. The name of gene symbol was listed in order of PIO/CONT Log2 ratio.
(a)
Gene symbol Description KEGG pathway PIO/CONT Log2 ratio
Olr1436 Olfactory receptor 1436 Olfactory transduction −3.27
Xylt1 Xylosyltransferase 1
Glycosaminoglycan biosynthesis-chondroitin
sulfate/glycosaminoglycan biosynthesis-heparan
sulfate/metabolic pathways
−3.03
Map3k10 Mixed-lineage kinase 2 MAPK signaling pathway −2.24
Icoslg — Cell adhesion molecules (CAMs)/intestinal immune
network for IgA production
−2.15
Scd1 Stearoyl-coenzyme A desaturase 1 Biosynthesis of unsaturated fatty acids/PPAR
signaling pathway
−2.01
Ucp1 Uncoupling protein 1 PPAR signaling pathway/Huntington’s disease −1.91
Oxt Oxytocin, prepropeptide Neuroactive ligand-receptor interaction −1.81
Chrm1 Cholinergic receptor, muscarinic 1
Calcium signaling pathway/Neuroactive
ligand-receptor interaction/regulation of actin
cytoskeleton
−1.75
Avp Arginine vasopressin
Neuroactive ligand-receptor interaction/vascular
smooth muscle contraction/vasopressin-regulated
water reabsorption
−1.58
Lpcat2 Lysophosphatidylcholine
acyltransferase 2
Glycerophospholipid metabolism/ether lipid
metabolism/metabolic pathways
−1.37
Il12rb1 Interleukin 12 receptor, beta 1 Cytokine-cytokine receptor interaction/jak-STAT
signaling pathway
−1.34
EDNRA Endothelin receptor type A
Calcium signaling pathway/neuroactive
ligand-receptor interaction/vascular smooth muscle
contraction
−1.30
Cfd Complement factor D (adipsin) Complement and coagulation cascades −1.20
Serpinb5 Serine (or cysteine) peptidase
inhibitor, clade B, member 5 p53 signaling pathway −1.19
Htr2b 5-Hydroxytryptamine (serotonin)
receptor 2B
Calcium signaling pathway/neuroactive
ligand-receptor interaction/gap junction
−1.19
Cox8b Cytochrome c oxidase, subunit
VIIIb
Oxidative phosphorylation/metabolic
pathways/cardiac muscle contraction/Alzheimer’s
disease/Parkinson’s disease/Huntington’s disease
−1.17
Peg12 Paternally expressed 12 Wnt signaling pathway −1.11
Sema3d
Sema domain, immunoglobulin
domain (Ig), short basic domain,
secreted, (semaphorin) 3D
Axon guidance −1.07
Atp1a2 ATPase, Na+/K+ transporting,
alpha 2 polypeptide
Cardiac muscle contraction/aldosterone-regulated
sodium reabsorption/proximal tubule bicarbonate
reclamation/salivary secretion/gastric acid secretion
−1.05
Dll3 Delta-like 3 Notch signaling pathway −1.05
Brca2 Breast cancer 2 Homologous recombination/pathways in
cancer/pancreatic cancer
−1.04
Aqp4 Aquaporin 4 (Aqp4), transcript
variant 2 Vasopressin-regulated water reabsorption −1.02
Gys2 Glycogen synthase 2 Starch and sucrose metabolism/insulin signaling
pathway
−1.01
KEGG pathway: Koto Encyclopedia of Gene and Genomes pathway.PPAR Research 7
(b)
Gene symbol Description KEGG pathway PIO/CONT Log2 ratio
Gucy2d Guanylate cyclase 2d (Gucy2d) Purine metabolism/olfactory
transduction/phototransduction 1.59
Cyp2b1
Cytochrome P450, family 2,
subfamily b, polypeptide 1
(Cyp2b1), mRNA
Arachidonic acid metabolism/retinol
metabolism/metabolism of xenobiotics by
cytochrome P450/drug metabolism-cytochrome
P450/metabolic pathways
1.45
Cyp2d3
Cytochrome P450, family 2,
subfamily d, polypeptide 3
(Cyp2d3)
Drug metabolism-cytochrome P450 1.20
Tarsl2 Threonyl-tRNA synthetase-like 2
(Tarsl2), mRNA Aminoacyl-tRNA biosynthesis 1.17
Prl Prolactin (Prl), mRNA
Cytokine-cytokine receptor interaction/neuroactive
ligand-receptor interaction/jak-STAT signaling
pathway
1.17
Olr1331 Olfactory receptor 1331
(Olr1331), mRNA Olfactory transduction 1.17
Dync1h1 Dynein cytoplasmic 1 heavy
chain 1 (Dync1h1), mRNA Phagosome/vasopressin-regulated water reabsorption 1.11
Olr297 Olfactory receptor 297 (Olr297) Olfactory transduction 1.06
KEGG pathway: Koto Encyclopedia of Gene and Genomes pathway.
to SD rats and was decreased by PIO treatment in PCK rats
(Figure 1(a)). On the other hand, the mRNA level of Ucp1
was not signiﬁcantly diﬀerent between PCK and SD rats
(data not shown).
Scd1 is involved in cell proliferation via growth factors
in some type of cancer cells [16–18]. To determine the
cellular distribution of Scd1 in PCK and SD kidneys,
immunohistochemistry was used. In normal SD kidneys,
Scd1 was hardly detected. On the other hand, in untreated
PCK kidneys, Scd1 was present in the cytoplasm of normal-
shaped tubule epithelia diﬀusely but not in growing cysts.
With PIO treatment, the distribution of Scd1 decreased in
those normal-shaped cells (Figures 1(b) and 1(c)). These
ﬁndings suggest that Scd1 may relate to the onset of renal
cyst formation originated from normal-shaped tubules.
4. Discussion
In our previous report, we demonstrated that PIO treat-
ment in PCK rats inhibited renal Raf/MEK/ERK and
AKT/mTOR/S6 activity and reduced proliferation of dis-
eased renal cells [10]. In the current study, we analyzed DNA
microarray using GSEA and KEGG pathway analysis in order
to detect gene-based eﬀects of PIO treatment [12, 13]. The
results of GSEA analysis of C5BP and C2CP are consistent
with our previous ﬁndings, as a number of gene sets related
to cell cycle and cell proliferation are downregulated in
kidneys of PIO-treated PCK rats.
Both EGF and PDGF pathways were downregulated
by PIO treatment (Table 3(a)). In PKD cystic epithelial
cells, growth factors such as EGF and PDGF activate the
Raf/MEK/ERK pathway via receptor binding and tyrosine
kinase activation [19–21]. Therefore, PIO may ameliorate
PKD in PCK rats by inhibiting cell proliferation through
suppression of the activity of EGF and PDGF pathways.
Further, in PKD patients, several reports show that cystic
kidneys have signiﬁcant levels of apoptosis [22, 23]. The JNK
pathway is known to have critical roles in cell apoptosis,
and JNK is overexpressed in cystic epithelial cells in Pkd1
conditional knockout mice [23, 24]. In the current study,
the JNK MAPK pathway also was downregulated by PIO
treatment. Therefore, PIO may have antiapoptotic eﬀects via
inactivation of the JNK pathway.
PIO, as well as other PPAR-γ agonists rosiglitazone and
troglitazone, is known to induce cell cycle arrest and cell
apoptosis in human cancer cells [25–27]. Although it has
recently been reported that rosiglitazone inhibits cell prolif-
erationbyinducingG1cellcyclearrestinADPKDcyst-lining
epithelial cells [28], the inhibitory mechanism of PIO is
understudiedinPKD.Inthecurrentanalysis,Brca2,BUB1B,
Cdkn1c, Cdkn2b, Chek1, and PLK1 were downregulated.
These genes are involved in cell cycle regulation, G0/G1,
G1/S and/or G2/M checkpoints [29–35], suggesting that the
antiproliferative eﬀect of PIO may be related to cell cycle
arrest.
After searching each gene expression with signiﬁcant
change by PIO treatment, we then focused on Scd1 because
it is known to stimulate cell proliferation in cancer cells
through phosphorylation of AKT [16–18], one of the
responsible kinases in cystic cell proliferation in PKD [10,
36]. Immunohistochemical analysis demonstrated that Scd1
expression was increased in noncystic tubules in PCK
kidneys, and PIOtreatment reduced its overexpression, sug-
gesting that Scd1 may relate to the onset of cell proliferation
in initial cyst formation through phosphorylation of AKT.
In addition, activation of the cell cycle increases syntheses
of phospholipids and cholesterol [37–39], and Scd1 controls
the balance of saturated and monounsaturated fatty acids,8 PPAR Research
S
c
d
1
/
G
A
P
D
H
 
r
a
t
i
o
PIO
#
CONT (vehicle) PIO CONT (vehicle)
PCK  Normal SD
4
3
2
1
0
∗
(a)
PIO CONT (vehicle)
PCK  Normal SD
CONT (vehicle)
50
(b)
Rat strain Treatment Cysts Noncystic tubules 
Normal SD CONT (vehicle)  0.3  0.1 
PIO 0.3 0.1  NS
PCK CONT (vehicle)  0  0 10.9  0.3 
PIO 0 0 6.2  0.7  ∗∗
−
−
±
±
±
± ±
±
(c)
Figure 1: Cellular expression and distribution of Scd1 in rodent polycystic kidneys. (a) Relative gene expression levels for Scd1.m R N A
expression levels are shown for vehicle-treted (CONT) or PIO-treated SD and PCK kidneys as compared to vehicle-treated (CONT) SD
kidneys (set to 1.0) (∗P<0.05 SD (CONT) versus PCK (CONT), #P<0.05 PCK (CONT) versus PCK (PIO)). Expression levels were
normalized to GAPDH. (b) Renal Scd1 distribution in vehicle-treated (CONT) or PIO-treated SD and PCK rats. Representative kidney
sections from vehicle-treated (CONT) or PIO-treated SD and PCK rats were stained with an antibody to Scd1.M o u s eI g G 2 b ,κ isotype
control antibody, did not show any reaction in the kidney. (c) Ratio of Scd1-positive cysts or noncystic tubules in kidney sections. Positive-
stained cysts or non-cystic tubules were counted in ﬁve random ﬁelds of kidney sections obtained from ﬁve rats in each group by a naive
observer using a 20x objective. (∗∗P<0.01 PCK (CONT) versus PCK (PIO) in noncystic tubules in the kidney section).
regulating the composition of cholesterol esters and phos-
pholipids in cell membrane structure [16]. Therefore, PIO
may reduce cell proliferation by the downregulation of Scd1
gene expression not only through reducing AKT signaling
activity but also through altering fatty acid synthesis. In
abnormal cell proliferation in cancer, Scd1 expression is
increased, and the cell proliferation is suppressed by treat-
ment with PPAR-γ agonists, although the changes in Scd1
expression are not always consistent [16, 40, 41]. On the
other hand, in diabetes mellitus with insulin resistance,PPAR Research 9
adipose tissue or skeletal muscle Scd1 expression is decreased
and increased by PPAR-γ agonists [42–44]. Therefore, the
expression level of Scd1 and the eﬀect of PPAR-γ ago-
nists may depend on the disease and/or the state of cell
proliferation.
Clinically, increased body weight, oedema, and urinary
bladder tumors are concerned as possible side eﬀects of
PPAR-γ agonists. Although those phenomena were not
observed in both genders of PCK rats in the current PIO
treatment, the eﬀect of longer term treatment with diﬀerent
doses will need to be studied carefully. Since ameliorative
eﬀects are reported in several animal models of PKD [8–10,
45], PPAR-γ agonists are thought to be a potential candidate
for therapeutic interventions in both ARPKD and ADPKD
patients.
5. Conclusions
In the current study, PIO reduced PKD progression and
altered the expression of renal genes involved in cell pro-
liferation, cell cycle progression, and fatty acid metabolism
in an orthologous rat model of human ARPKD. In addition
to the previously demonstrated inhibition of Raf/MEK/ERK
and AKT/mTOR/S6 signaling pathways by treatment of PCK
rats with 10mg/kg PIO for 16 weeks [10], suppression of cell
proliferationmayalsoberelatedtoreductionsinEGF,PDGF,
and JNK pathways, cell cycle arrest related to Brca2, BUB1B,
Cdkn1c, Cdkn2b, Chek1, and PLK1 genes, and alteration of
fatty acid metabolism related to Scd1.
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